Browse News
Filter News
Found 15 articles
-
AstraZeneca Full year and Q4 2023 Financial Results
2/8/2024
Strong growth and pipeline momentum with three new medicines approved since the third quarter
-
Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage
4/4/2023
Rocket Pharmaceuticals, Inc., a leading late-stage biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare disorders with high unmet need, announced expansion of its leadership team to support its growing and industry-leading pipeline of AAV and LV gene therapy assets and evolution towards commercial stage.
-
Feinstein Institutes-Led Lupus Phase 2 Clinical Trial Shows Promise of an Investigational Drug
9/16/2022
Northwell Health’s Division of Rheumatology and The Feinstein Institutes for Medical Research recently published in the New England Journal of Medicine (NEJM) data showing that an experimental lupus therapy reduced disease activity in joints of patients and globally improved their condition.
-
Biogen announced that its mid-stage monoclonal antibody litifilimab is showing promise in reducing joint pain related to systemic lupus erythematosus (SLE) lupus.
-
Last year, the FDA's Center for Drug Evaluation and Research approved 50 drugs. A new study found that 33, or 66% of them, were supported with genomic data.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
5/27/2022
The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN).
-
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
SAPHNELO Consistently Reduces Systemic Lupus Erythematosus Disease Activity Regardless of Disease Duration and Prior Treatment
11/1/2021
New subgroup analyses from the TULIP Phase III clinical trial program showed SAPHNELO, a first-in-class type I interferon antagonist, in addition to standard therapy, resulted in a greater reduction in systemic lupus erythematosus disease activity regardless of disease duration, standard therapy type and prior treatment, compared to standard therapy alone.
-
Seventeen years after buying global rights, AstraZeneca is finally announcing a win for the lupus community with an FDA approval for Saphnelo.
-
SAPHNELO (anifrolumab) Approved in the US for Moderate to Severe Systemic Lupus Erythematosus
8/2/2021
AstraZeneca’s SAPHNELO™ has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus who are receiving standard therapy.
-
Lupus Foundation of America Celebrates FDA Approval of Saphnelo™ (Anifrolumab-fnia) as a New Treatment for Lupus
8/2/2021
The U.S. Food and Drug Administration (FDA) has approved Saphnelo™ (anifrolumab-fnia) as a treatment for adults with systemic lupus erythematosus (SLE) who are receiving standard therapy.
-
Lupus Research Alliance Applauds U.S. FDA Approval of AstraZeneca's anifrolumab-fnia (Saphnelo™) for Systemic Lupus Erythematosus (SLE)
8/2/2021
The Lupus Research Alliance is particularly excited about the U.S. Food and Drug Administration approval of anifrolumab-fnia, a first in class, type I interferon receptor antagonist, indicated for adults with moderate to severe systemic lupus erythematosus.
-
Newly Approved Lupus Drug Based on Discoveries Made in HSS Lab
8/2/2021
On August 2, 2021, the US Food and Drug Administration approved the drug anifrolumab (Saphnelo) for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE) who are receiving standard therapy.